시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
비소세포폐암 시장 규모, 점유율, 성장 분석 : 유형별, 치료법별, 최종 이용 산업별, 지역별 - 산업 예측(2025-2032년)
Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Type (Adenocarcinoma, Squamous Cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy), By End-Use Industry, By Region - Industry Forecast 2025-2032
상품코드 : 1622408
리서치사 : SkyQuest
발행일 : 2024년 12월
페이지 정보 : 영문 165 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,652,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,951,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,250,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

비소세포폐암 시장 규모는 2023년 269억 4,000만 달러로 평가되며, 2024년 306억 8,000만 달러에서 2032년 869억 4,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 13.9%의 CAGR로 성장할 것으로 예상됩니다.

면역관문억제제(ICI)가 1차 치료제로 도입되면서 비소세포폐암(NSCLC) 분야의 시장 매출 성장이 크게 촉진되고 있습니다. 전 세계 폐암 환자의 80-85%를 차지하는 비소세포폐암의 높은 유병률은 주요 기업들이 혁신적인 치료법을 개발하고 기존 치료제의 효능을 개선하는 데 집중하도록 유도하고 있습니다. 이러한 성장세는 폐암이 전 세계 암 관련 사망의 주요 원인이라는 평가와 함께 비소세포폐암 진단 건수의 증가와 선진국과 신흥국 모두에서 사회적 인식이 높아지면서 시장 역동성을 더욱 증폭시키고 있습니다. 또한, 비소세포폐암 치료제를 파이프라인에 포함시키려는 주요 시장 기업들의 노력과 연구개발에 대한 투자 증가도 세계 시장 확대에 중요한 요인으로 작용하고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

비소세포폐암 시장 규모 : 유형별

비소세포폐암 시장 규모 : 치료법별

비소세포폐암 시장 규모 : 최종 이용 산업별

비소세포폐암 시장 규모

경쟁 정보

주요 기업 개요

결론과 추천사항

ksm
영문 목차

영문목차

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

The introduction of immune checkpoint inhibitors (ICIs) for first-line treatment is significantly propelling market revenue growth in the non-small cell lung cancer (NSCLC) sector. Representing 80-85% of lung cancer cases globally, NSCLC's prevalence has prompted leading companies to focus on developing innovative therapies and enhancing the efficacy of existing options. This growth is also driven by lung cancer's reputation as a leading cause of cancer-related deaths worldwide. Rising diagnoses of NSCLC, coupled with increased public awareness in both developed and developing countries, are further amplifying market dynamics. Additionally, the commitment of major market players to incorporate NSCLC medications into their pipelines and their heightened investment in research and development are crucial factors driving the expansion of the global market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Non-Small Cell Lung Cancer Market Segmental Analysis

Global Non-Small Cell Lung Cancer Market is segmented by type, treatment, end-use industry and region. Based on type, the market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and large cell neuroendocrine tumors. Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Based on end-use industry, the market is segmented into hospitals, homecare, specialty clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer (NSCLC) market is primarily driven by the escalating incidence of lung cancer attributed to factors such as smoking, air pollution, and increased vulnerability due to HIV infection, alongside a growing population. Additionally, the market is expected to expand with the rising number of regulatory approvals for innovative therapies tailored to NSCLC. Key industry players are prioritizing research and development investments to address the surging demand for effective treatment options. This combination of increasing disease prevalence and advancements in drug approvals is poised to significantly enhance the growth trajectory of the NSCLC market in the upcoming years.

Restraints in the Non-Small Cell Lung Cancer Market

A significant challenge facing the non-small cell lung cancer market is the high cost associated with its treatment options. While effective therapies such as chemotherapy, surgery, targeted therapies, radiation, and immunotherapy are available, they come with substantial financial burdens. This expensive nature of treatment poses a barrier to accessing care, limiting affordability for many patients and ultimately restricting market growth. Consequently, the financial implications of these therapies can hinder the overall advancement of the non-small cell lung cancer market, making it difficult for a broader population to benefit from available treatment options.

Market Trends of the Non-Small Cell Lung Cancer Market

The non-small cell lung cancer (NSCLC) market is witnessing significant growth, driven by a rise in diagnoses and heightened awareness across global regions, both developed and developing. Innovative treatment options, including targeted therapies and immunotherapies, are being actively developed by leading pharmaceutical companies, expanding their portfolios. Increased investment in research and development from major players is enhancing treatment availability and efficacy, further stimulating market momentum. Additionally, supportive regulatory frameworks and healthcare initiatives are improving patient access to advanced therapies, positioning the NSCLC market for sustained growth in the coming years as it aligns with evolving medical needs and technological advancements.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Non-Small Cell Lung Cancer Market Size by Type & CAGR (2025-2032)

Global Non-Small Cell Lung Cancer Market Size by Treatment & CAGR (2025-2032)

Global Non-Small Cell Lung Cancer Market Size by End-Use Industry & CAGR (2025-2032)

Global Non-Small Cell Lung Cancer Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기